PixarBio (OTCQB: PXRB) is a specialty pharmaceutical/biotechnology company focused on pre-clinical and clinical commercial development of novel neurological drug delivery systems for post-operative pain, according to the company’s website (see here: www.PixarBio.com). SNNLive spoke with Frank Reynolds, CEO of PixarBio Corporation at the OTCQB Executive Forum at the OTC Markets site in New York City, NY.
In this video interview, Mr. Reynolds and our host discuss the following topics:
- Overview of PixarBio
- Where the science comes from
- Mr. Reynolds background and why he started PixarBio
- Size of the post-operative pain market
- Product development
- Patent portfolio
- Clinical development
- Goals and milestones for 2017
For more information about PixarBio Corporation, please visit: www.PixarBio.com
The interview may contain forward-looking statements about PixarBio Corporation. See PixarBio's periodic filings with the Securities and Exchange Commission for more complete information.
© 2017 Stock News Now
Supported by Superior Web Solutions